Rheumatoid arthritis: Emerging evidence for the benefits of early and aggressive therapy

Disease Management and Health Outcomes

Volumn 1, Issue 3, 1997, Pages 141-153

  Tugwell, Peter ^a,c   Ortiz, Zulma ^a   Griffiths, Bridget ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001675376     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199701030-00004     Document Type: Article

References (92)

1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123-51
2. Reilly PA, Cosh JA, Maddison PJ, et al. Mortality and survival in rheumatoid arthritis. A 25-year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9
3. Gordon DA, Hastings DE. Rheumatoid arthritis clinical features. In: Klippel JH, Dieppe PA, editors. Rheumatology. St Louis: C.V. Mosby, 1994: 3.4.1-14
4. van de Putte L, Weinblatt M. Radical intervention in early rheumatoid arthritis. The case for enteric-coated sulphasalazine, methotrexate and combination therapy. Br J Rheumatol 1995; 34 Suppl. 2: 1
5. Epstein W. Efficacy of standard slow-acting antirheumatic drugs. Semin Arthritis Rheum 1994; 23 (6): 32-8
6. Fuchs H, Kaye J, Callahan L, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91
7. Caruso I, Santandrea S, Sarzi Puttini P, et al. Clinical laboratory and radiographic features for early RA. J Rheumatol 1990; 17: 1268-73
8. Van der Heijde D, van Leeuwen M, van Riel P, et al. Bi-annual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34
9. Brook A, Corbett M. Radiographic changes in early rheumatic disease. Ann Rheum Dis 1977; 36: 71-3
10. Wilske K, Healey L. Remodelling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565-7
11. Bensen WG, Bensen W, Adachi J, et al. Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 1990; 17: 987-9
12. Fries J. Re-evaluating the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. J Rheumatol 1990; 17: 12-5
13. Wilke W, Clough J. Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991; 21: 21-34
14. Wilke W, Sweeney T, Calabrese L. Early, aggressive therapy for rheumatoid arthritis: concerns, description and estimate of outcome. Semin Arthritis Rheum 1993; 23 Suppl. 1: 26-41
15. McGuire J, Ridgway W. Aggressive drug therapy for rheumatoid arthritis. Hosp Pract 1993; 28 (9): 45-52
16. Wilske K, Healey L. The need for aggressive therapy of rheumatoid arthritis. Rheum Dis Clin North Am 1993; 19 (1): 153-61
17. Wilske K. Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum 1993; 23 (2): 11-8
18. Kremer J. The changing face of therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21 (3): 845-52
19. Jaffe I. New approaches to the management of rheumatoid arthritis. J Rheumatol 1992; 19: 2-8
20. McCarty D. Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination. Semin Arthritis Rheum 1993; 23 (2): 42-9
21. Furst D. Combination DMARD therapy: rationale and limitations. Rheumatol Eur 1995; 24 Suppl. 2: 190-4
22. Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995; 34 Suppl. 2: 87-90
23. Arnett F, Edworthy S, Bloch D, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
24. van Zeben D, Hazes J, Breedveld F, et al. Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 1993; 20: 1288-96
25. Young A. Short-term outcomes in recent onset rheumatoid arthritis. Br J Rheumatol 1995; 35 Suppl. 2: 79-86
26. Hench P, Kendall E, Slocomb C, et al. The effect of a hormone of the adrenal cortex (17 OH 11 dehydrocorticosterone: compound E) and a pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Proceedings of staff meetings of Mayo Clinic 1949; 24: 181-97
27. Masi A, Maldonado-Cocco JA, Kaplan S, et al. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum 1976; 4: 299-326
28. Paulus H, Scott D, Edmonds J. Classification of antirheumatic drugs. Arthritis Rheum 1992; 35: 364-5
29. Cash J, Klippel J. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75
30. Conaghan P, Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, amimalarials, and D-penicillamine. Curr Opin Rheumatol 1995; 7: 167-73
31. Van der Heijde A, Jacobs J, Bijlsma J, et al. The effectiveness of early treatment with second line antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124: 699-707
32. Felson D, Anderson J, Meenan R. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994; 37: 1487-91
33. Felson D, Anderson J, Meenan R. Use of short-term efficacy/toxicity tradeoffs select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992; 35: 117-25
34. Fries J, Williams C, Ramey D, et al. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306
35. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995; 98: 156-68
36. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993; 119: 1067-71
37. Schnabel A, Gross W. Low-dose methotrexate in rheumatic diseases: efficacy, side effects and risk factors for side effects. Semin Arthritis Rheum 1994; 23: 310-27
38. Williams H, Wilkens R, Samuelson C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28: 721-30
39. Weinblatt M, Coblyn J, Fox D, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N End J Med 1985; 312: 818-22
40. Thompson R, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760-3
41. Andersen P, West S, O'Dell J. et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103: 489-96
42. Furst D, Koehnke R, Burmeister L, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20
43. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990; 33 (10): 1449-61
44. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 358-66
45. Furst D. Should methotrexate be used to treat early rheumatoid arthritis? Semin Arthritis Rheum 1994; 23 Suppl. 2: 39-43
46. Bannwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis: an update. Drugs 1994; 47 (1): 25-50
47. Furst D, Kremer J. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 305-14
48. Weinblatt M, Maier A. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol 1990; 17 Suppl. 22: 33-8
49. Pullar T, Hunter J, Capell H. Which component of sulphasalazine is active in rheumatoid arthritis? BMJ 1985; 290: 1535-8
50. McConkey B, Crockson R, Wilkinson A. The effect of some anti-inflammatory drugs on the acute phase protein response in rheumatoid arthritis. BMJ 1980; 1: 442-4
51. The Australian Multicentre Clinical Trial Group. Sulphasalazine in early rheumatoid arthritis. J Rheumatol 1992; 19(11): 1672-7
52. Van der Heijde D, van Riel P, Nuver-Zwart I, et al. Effects of HCQ and SSZ on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8
53. Hannonen P, Mottenen T, Hakola M, et al. Sulphasalazine in early rheumatoid arthritis. A 48-week double-blind prospective placebo-controlled study. Arthritis Rheum 1993; 36 (11): 1501-9
54. Bax D, Amos R. Sulphasalazine: a safe effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Ann Rheum Dis 1985; 44: 194-8
55. Wolfe F. The curious case of intramuscular gold. Rheum Dis Clin North Am 1993; 19(1): 173-87
56. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early second-line therapy: 5-year follow-up of a prospective double-blind placebo-controlled study. J Rheumatol 1995; 22 (12): 2208-13
57. Borg G, Allander E, Lund B, et al. Results from a 2-year, double-blind placebo-controlled study. J Rheumatol 1988; 15: 1747-54
58. Tugwell P. International consensus recommendations on cyclosporin use in rheumatoid arthritis. Drugs 1995; 50 Suppl. 1: 48-56
59. Richardson C, Emery P. Clinical use of cyclosporin in rheumatoid arthritis. Drugs 1995; 50 Suppl. 1: 26-36
60. Dijkmans B. Safety aspects of cyclosporin in rheumatoid arthritis. Drugs 1995; 50 Suppl. 1: 41-7
61. Pasero G, for GRISAR. Slow progression of joint damage in early rheumatoid arthritis [abstract]. Arthritis Rheum 1995; 38 (9): 777
62. Mueller E, Kovarik J, van Bree J, et al. Improved dose linearity of cyclosporin pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11 (2): 301-4
63. Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs 1995; 50 (5): 951-68
64. Dwosh I, Stein B, Urowitz M, et al. Azathioprine in early rheumatoid arthritis, comparison with gold and chloroquine. Arthritis Rheum 1977; 20: 685-92
65. Boers M, Ramsden M. Long-acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18: 316-24
66. Tugwell P, Boers M. Long-acting drug combinations in rheumatoid arthritis: updated overview. In: Wolfe T, Pincus T, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome, treatment. New York: Marcel Dekker, Inc., 1994: 335-71
67. Corkill M, Kirkham B, Chikanza I, et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized clinical trial. Br J Rheumatol 1990; 29: 274-9
68. Williams H, Ward J, Reading J, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35: 259-69
69. Wilkens R, Urowitz M, Stablein D, et al. Comparison of azathioprine, methotrexate and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35: 849-56
70. Scott D, Dawes P, Tunn E, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis. Br J Rheumatol 1989; 28: 128-33
71. Smyth C, Bartholomew B, Mills D, et al. Cyclophosphamide therapy for rheumatoid arthritis. Arch Intern Med 1975; 135: 789-93
72. Gibson T, Emery P, Armstrong R, et al. Combined D-penicillamine and choroquine treatment of rheumatoid arthritis: a comparative study. Br J Rheumatol 1987; 27: 279-84
73. Sackett DL, Haynes RB, Guyatt GH, et al. Clinical epidemiology. A basic science for clinical medicine. 2nd ed. Boston: Little, Brown and Company, 1991
74. Wilkens R, Sharp J, Stablein D, et al. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologie outcome assessment. Arthritis Rheum 1995; 38 (12): 1799-806
75. Taggart A, Hill J, Astbury C, et al. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol 1987; 26: 32-6
76. O'Dell J, Haire C, Erikson N, et al. Triple DMARD therapy for rheumatoid arthritis: efficacy. N Engl J Med 1996; 334 (2): 1287-91
77. Haagsma C, van de Putte L, van Riel P. Sulfasalazine, methotrexate and the combination in early RA, a double blind randomised study. Arthritis Rheum 1995; 38 Suppl.: S368
78. Bensen WG, Tugwell P, Roberts R, et al. Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21(11): 2034-8
79. Porter D, Capell H, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993; 20 (4): 645-9
80. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333 (3): 137-41
81. Felson D, Anderson J, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38 (6): 727-35
82. Harris E, Emkey R, Nichols J, et al. Low dose prednisone therapy in rheumatoid arthritis: a double-blind study. J Rheumatol 1983; 10 (5): 713-21
83. Kirwan J. The effect of glucocorticoids on joint destruction in RA. N Engl J Med 1995; 333 (3): 142-6
84. Larsen A, Dale K, Rek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977; 18: 481-91
85. Shelter Y, Bloch D, Mitchell D, et al. Disability in RA comparison of prognostic factors across three populations. J Rheumatol 1987; 14: 705-9
86. Fries J, Williams C, Bloch D, et al. Non-steroidal anti-inflammatory drug-induced gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22
87. Wolfe F, Mitchell D, Sibley J, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94
88. Scott D, Symmons D. The mortality of rheumatoid arthritis. In: Butler RC, Jayson MIV, editors. Collected reports on the rheumatic diseases. Arthritis and Rheumatism Council for Research, 1995: 45-8
89. Saag K, Koehnke R, Caldwell J, et al. Low-dose, long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23
90. Kirwan J. [Discussion to comment on article in N Engl J Med 1995; 333 (3): 142-6]. N Engl J Med 1995; 333 (3): 1570
91. Dequeker J, Westhovens R. Low-dose corticosteroid-associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention [editorial]. J Rheumatol 1995; 22: 1013-9
92. The OMERACT Committee. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Maastricht, The Netherlands; 1992 Apr 29-May 3. J Rheumatol 1993; 20: 527-91